Inicio・Lista de Acciones・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Abierto

SectorSanidad

2.25 -5.86

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

2.22

Máximo

2.39

Métricas clave
By Trading Economics
Ingresos	14M -1M
Ventas	16M 21M
BPA	-0.003
Margen de beneficios	-4.943
Empleados	81
EBITDA	15M 657K

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+91.18% upside

Dividendos
By Acuity
Próximas Ganancias	5 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	324M 1B
Apertura anterior	8.11
Cierre anterior	2.25

Noticias sobre sentimiento de mercado

By Acuity

50%

145 / 340 Clasificación en Healthcare

Lexicon Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

21 jul 2026, 19:42 UTC

Lexicon Pharmaceuticals is higher as the market gains momentum, driven by strong performances from major companies and a resurgence in semiconductor stocks.

20 jul 2026, 19:06 UTC

Lexicon Pharmaceuticals Inc shares are lower today, following three days of gains. Broader market declines are linked to rising US Treasury yields and oil prices above $90.

Comparación entre iguales

Cambio de precio

Lexicon Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

91.18% repunte

Estimación a 12 Meses

Media 4.55 USD 91.18%

Máximo 6 USD

Mínimo 3.1 USD

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Lexicon Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

2 ratings

Comprar

Mantener

Vender

De acuerdo con 2 analistas que ofrecen calificaciones bursátiles a para Lexicon Pharmaceuticals Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

145 / 340 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.